Jeena Sikho Lifecare Ltd

- No explicit or direct mention of any current or future fundraising through debt or equity was found in the provided transcript excerpts. - The management emphasized maintaining profitability and organic growth through increasing occupancy, launching new products (OTC segment), and tie-ups, without indicating plans for raising external capital. - The company also mentioned avoiding loan-based business models and focusing on self-sustained growth and cash-based sales. - There was no discussion on issuing new equity or debt instruments, nor any elaboration on fundraising plans during the call. - Operations and expansions appear to be funded through internal accruals and partnerships (e.g., college tie-ups) rather than external fundraising at this point.

- Target turnover of INR 700 crores for the year, maintaining 20%-25% PAT margin (Page 20). - OTC (over-the-counter) product launch on July 22, 2025, expected to add incremental revenue; turnover target of INR 500 crores from OTC in 1.5 to 2 years (Pages 17, 12). - Plans to launch 6-7 new products before March 31, 2026, and 15-20 products in the next year, aiming for INR 500 crores turnover from products in 1.5 to 2 years with 20% PAT margin (Page 20). - Volume growth seen in medicines; Q1 2025 saw 125,000 people taking medicines, annualized to potentially 500,000 (Page 30). - Bed capacity expansion target from 2,570 to 2,850-3,000 beds by March 31, 2026, and 7,000-10,000 beds in 3-5 years to drive healthcare service sales (Pages 19, 20). - Increasing number of hospitals (from 50 to 55) and clinics, including international expansion (Dubai, Nepal) (Page 12, 9).

- Revenue grew 74% YoY to INR 174 crores in Q1 FY '26; similar growth expected as OTC product launches scale. - EBITDA margin was strong at 45% in Q1 FY '26; management targets a healthy net profit margin of 20%-25% going forward. - PAT grew 218% YoY to INR 51 crores in Q1 FY '26; profitability expected to increase with controlled expenses and growing volumes. - Direct expenses on medicines are maintained at 15% (medicine purchase) and 9% (consumption), indicating stable cost control. - Expanding bed capacity targeting 7,000-10,000 beds in 3-5 years, implying long-term revenue growth. - OTC product launch expected to add INR 500 crores turnover in 1.5-2 years, broadening revenue base. - Operating expenses are being optimized through vendor negotiations and cost control committees, likely sustaining margin expansion. - ESOP cost impact is minor and spread over 5 years, causing minimal profitability dilution. Overall, management anticipates steady revenue growth, healthy 20-25% net margin, and improving profitability with scale and cost discipline.

The transcript does not explicitly mention the current or expected order book or pending orders for Jeena Sikho Lifecare Limited. However, relevant details indicating growth and demand include: - In Q1 FY 2025-26, 1,25,000 people took medicines; extrapolated to an estimated 5,00,000 annually if the run rate maintains. - OTC product launch on 22nd July with strong initial demand: 21 orders in the first hour, quick stock depletion in 4 days. - Plans to expand OTC turnover to INR 500 crores in 1.5 to 2 years. - Medicine sales grew from INR 63 crores in Q4 to INR 80 crores in Q1. - Hospital beds expanding rapidly with 2,570 operational beds, targeting 2,850 by March 2026. - Expansion through tie-ups with Ayurvedic colleges and plans for 7,000-10,000 beds in 3-5 years. - Profitable growth with maintained margins expected. No direct order book figure disclosed.

- The company plans to add 1,000 beds per year as part of its long-term growth, targeting 7,000 to 10,000 beds in 3 to 5 years. - Considering the acquisition of a large hospital with 1,000 beds is under discussion. - Focus on opening clinic franchises, hospitals, and daycare franchises across regions (south, east, west, north) to expand reach. - New product launches are planned: 6-7 products before March 31, 2026, and 15-20 products next year aiming for INR 500 crore turnover from product sales within 1.5 to 2 years. - Investment in in-house ERP and software development for improved operational efficiency. - Cost control committees established to optimize operating expenses. - Strategic marketing efforts include engaging distributors and franchises without heavy upfront marketing loans or expenses.